Pneumovax-23

BIOLOGICAL3 trials

Sponsors

University of California, Davis, GPN Vaccines

Conditions

AspleniaPneumococcal Infections

Phase 1

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

CompletedNCT05667740

GPN VaccinesPneumococcal Infections

Start: 2023-01-16End: 2023-10-08Updated: 2024-09-05

Extension Safety and Immunogenicity Study of GPNV-001

CompletedNCT05982314

GPN VaccinesPneumococcal Infections

Start: 2023-07-17End: 2024-08-30Updated: 2024-12-18

Phase 2

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

RecruitingNCT02232191

University of California, DavisAsplenia

Start: 2014-12-01End: 2027-07-01Target: 75Updated: 2026-08-18